Literature DB >> 18342630

Store-operated Ca(2+) channels and Stromal Interaction Molecule 1 (STIM1) are targets for the actions of bile acids on liver cells.

Edoardo C Aromataris1, Joel Castro, Grigori Y Rychkov, Greg J Barritt.   

Abstract

Cholestasis is a significant contributor to liver pathology and can lead to primary sclerosis and liver failure. Cholestatic bile acids induce apoptosis and necrosis in hepatocytes but these effects can be partially alleviated by the pharmacological application of choleretic bile acids. These actions of bile acids on hepatocytes require changes in the release of Ca(2+) from intracellular stores and in Ca(2+) entry. However, the nature of the Ca(2+) entry pathway affected is not known. We show here using whole cell patch clamp experiments with H4-IIE liver cells that taurodeoxycholic acid (TDCA) and other choleretic bile acids reversibly activate an inwardly-rectifying current with characteristics similar to those of store-operated Ca(2+) channels (SOCs), while lithocholic acid (LCA) and other cholestatic bile acids inhibit SOCs. The activation of Ca(2+) entry was observed upon direct addition of the bile acid to the incubation medium, whereas the inhibition of SOCs required a 12 h pre-incubation. In cells loaded with fura-2, choleretic bile acids activated a Gd(3+)-inhibitable Ca(2+) entry, while cholestatic bile acids inhibited the release of Ca(2+) from intracellular stores and Ca(2+) entry induced by 2,5-di-(tert-butyl)-1,4-benzohydro-quinone (DBHQ). TDCA and LCA each caused a reversible redistribution of stromal interaction molecule 1 (STIM1, the endoplasmic reticulum Ca(2+) sensor required for the activation of Ca(2+) release-activated Ca(2+) channels and some other SOCs) to puncta, similar to that induced by thapsigargin. Knockdown of Stim1 using siRNA caused substantial inhibition of Ca(2+)-entry activated by choleretic bile acids. It is concluded that choleretic and cholestatic bile acids activate and inhibit, respectively, the previously well-characterised Ca(2+)-selective hepatocyte SOCs through mechanisms which involve the bile acid-induced redistribution of STIM1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342630     DOI: 10.1016/j.bbamcr.2008.02.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Transient receptor potential canonical channel 1 impacts on mechanosignaling during cell migration.

Authors:  Anke Fabian; Jessica Bertrand; Otto Lindemann; Thomas Pap; Albrecht Schwab
Journal:  Pflugers Arch       Date:  2012-10-11       Impact factor: 3.657

Review 2.  STIM proteins: dynamic calcium signal transducers.

Authors:  Jonathan Soboloff; Brad S Rothberg; Muniswamy Madesh; Donald L Gill
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09       Impact factor: 94.444

Review 3.  Review of experimental animal models of biliary acute pancreatitis and recent advances in basic research.

Authors:  Mei H Wan; Wei Huang; Diane Latawiec; Kun Jiang; David M Booth; Victoria Elliott; Rajarshi Mukherjee; Qing Xia
Journal:  HPB (Oxford)       Date:  2012-02       Impact factor: 3.647

4.  Properties of Orai1 mediated store-operated current depend on the expression levels of STIM1 and Orai1 proteins.

Authors:  N Scrimgeour; T Litjens; L Ma; G J Barritt; G Y Rychkov
Journal:  J Physiol       Date:  2009-04-29       Impact factor: 5.182

Review 5.  STIMulating store-operated Ca(2+) entry.

Authors:  Michael D Cahalan
Journal:  Nat Cell Biol       Date:  2009-06       Impact factor: 28.824

6.  HMGB1 release by H2O2-induced hepatocytes is regulated through calcium overload and 58-F interference.

Authors:  Pei Zhao; Tingjie Ye; Xiaofeng Yan; Xudong Hu; Ping Liu; Xiaoling Wang
Journal:  Cell Death Discov       Date:  2017-04-10

7.  The action of selective CRAC channel blockers is affected by the Orai pore geometry.

Authors:  Isabella Derler; Rainer Schindl; Reinhard Fritsch; Peter Heftberger; Maria Christine Riedl; Malcolm Begg; David House; Christoph Romanin
Journal:  Cell Calcium       Date:  2012-12-05       Impact factor: 6.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.